บทบาทของรังสีรักษาและเคมีบำบัดในมะเร็งมดลูก
References
Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95:S105-43.
Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005,23:3668-75.
Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006;107:1823-30.
Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:11-8.
Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center.
Gynecol Oncol 2006;103:714-8.
Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G,et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16.
ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial) : a randomised study. Lancet 2009;373:125-36.
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-41.
Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-27.
Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834-8.
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma : a Gynecologic Oncology Group study.
Gynecol Oncol 2004;92:744-51.
ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review,
and meta-analysis. Lancet 2009;373:137-46.
R. A. Nout, H. Putter, I. M. Jurgenliemk-Schulz, J. J. Jobsen, L. C. Lutgens, E. M. van der Steen-Banasik, et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized
PORTEC-2 trial. J Clin Oncol 2008;26:abstr LBA5503
Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer : systematic review and meta-analysis. BJOG 2007;114: 1313-20.
Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial
Carcinoma Trial. J Clin Oncol 2004;22:1234-41.
Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, McKee B, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys
2002;54:79-85.
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 2001;51:1246-55.
Petignat P, Jolicoeur M, Alobaid A, Drouin P, Gauthier P, Provencher D, et al. Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecol Oncol 2006;101:445-9.
Jobsen JJ, Schutter EM, Meerwaldt JH, Van Der Palen J, Van Der Sijde R, Ten Cate LN, et al. Treatment results in women with clinical stage I and pathologic stage II endometrial carcinoma. Int J Gynecol Cancer 2001;11:49-53.
Tebeu PM, Popowski Y, Verkooijen HM, Bouchardy C, Ludicke F, Usel M, et al. Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis. Br J Cancer 2004;91:720-4.
Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 2001;82:338-43.
Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma : results of a randomised trial. Br J Cancer 2006;95:266-71.
Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer : a Japanese
Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-33.
Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback NB, Kurman R, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II : a Gynecologic
Oncology Group Study. Gynecol Oncol 1990;36:166-71.
Kuoppala T, Menp J, Tomas E, Puistola U, Salmi T, Grenman S, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol 2008;110:190-5.
Hogberg T, Rosenberg P, Kristensen G, de Oliveira CF, de Pont Christensen R, Sorbe B, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) + chemotherapy (CT) in early-stage high-risk endometrial cancer
(NSGO-EC-9501/EORTC 55991). J Clin Oncol 2007;25:[abstract 5503].
Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer.
Gynecol Oncol 2006;103:155-9.
National Cancer Institute. PORTEC 3. Available from : http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=521447&protocolsearchid=5821250&version= health professional
Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer : a gynecologic oncology group study. Gynecol Oncol 2005;
97:755-63.
Reisinger SA, Asbury R, Liao SY, Homesley HD. A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1996;63:299-303.
Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS. Sequential chemotherapy and irradiation in advanced stage endometrial cancer : A gynecologic oncology group phase I trial of doxorubicin-cisplatin followed by whole abdomen
irradiation. Gynecol Oncol 2009 ; [Epub ahead of print].
Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma : a Gynecologic Oncology Group
Study. J Clin Oncol 2006;24:36-44.
Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
Ann Oncol 2003;14:441-8.
Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;22:3902-8.
Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol
2004;22:2159-66.
Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM A, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A
Gynecologic Oncology Group study. Gynecol Oncol 2008;[Epub ahead of print].
Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer : a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409-20.
Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 2008;18:803-8.
National Cancer Institute. GOG 0209. Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=305940&protocolsearchid=5821250&version= health professional
Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005,23:3668-75.
Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006;107:1823-30.
Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:11-8.
Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center.
Gynecol Oncol 2006;103:714-8.
Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G,et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16.
ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial) : a randomised study. Lancet 2009;373:125-36.
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-41.
Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-27.
Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834-8.
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma : a Gynecologic Oncology Group study.
Gynecol Oncol 2004;92:744-51.
ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review,
and meta-analysis. Lancet 2009;373:137-46.
R. A. Nout, H. Putter, I. M. Jurgenliemk-Schulz, J. J. Jobsen, L. C. Lutgens, E. M. van der Steen-Banasik, et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized
PORTEC-2 trial. J Clin Oncol 2008;26:abstr LBA5503
Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer : systematic review and meta-analysis. BJOG 2007;114: 1313-20.
Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial
Carcinoma Trial. J Clin Oncol 2004;22:1234-41.
Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, McKee B, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys
2002;54:79-85.
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 2001;51:1246-55.
Petignat P, Jolicoeur M, Alobaid A, Drouin P, Gauthier P, Provencher D, et al. Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecol Oncol 2006;101:445-9.
Jobsen JJ, Schutter EM, Meerwaldt JH, Van Der Palen J, Van Der Sijde R, Ten Cate LN, et al. Treatment results in women with clinical stage I and pathologic stage II endometrial carcinoma. Int J Gynecol Cancer 2001;11:49-53.
Tebeu PM, Popowski Y, Verkooijen HM, Bouchardy C, Ludicke F, Usel M, et al. Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis. Br J Cancer 2004;91:720-4.
Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 2001;82:338-43.
Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma : results of a randomised trial. Br J Cancer 2006;95:266-71.
Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer : a Japanese
Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-33.
Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback NB, Kurman R, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II : a Gynecologic
Oncology Group Study. Gynecol Oncol 1990;36:166-71.
Kuoppala T, Menp J, Tomas E, Puistola U, Salmi T, Grenman S, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol 2008;110:190-5.
Hogberg T, Rosenberg P, Kristensen G, de Oliveira CF, de Pont Christensen R, Sorbe B, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) + chemotherapy (CT) in early-stage high-risk endometrial cancer
(NSGO-EC-9501/EORTC 55991). J Clin Oncol 2007;25:[abstract 5503].
Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer.
Gynecol Oncol 2006;103:155-9.
National Cancer Institute. PORTEC 3. Available from : http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=521447&protocolsearchid=5821250&version= health professional
Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer : a gynecologic oncology group study. Gynecol Oncol 2005;
97:755-63.
Reisinger SA, Asbury R, Liao SY, Homesley HD. A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1996;63:299-303.
Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS. Sequential chemotherapy and irradiation in advanced stage endometrial cancer : A gynecologic oncology group phase I trial of doxorubicin-cisplatin followed by whole abdomen
irradiation. Gynecol Oncol 2009 ; [Epub ahead of print].
Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma : a Gynecologic Oncology Group
Study. J Clin Oncol 2006;24:36-44.
Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
Ann Oncol 2003;14:441-8.
Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;22:3902-8.
Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol
2004;22:2159-66.
Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM A, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A
Gynecologic Oncology Group study. Gynecol Oncol 2008;[Epub ahead of print].
Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer : a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409-20.
Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 2008;18:803-8.
National Cancer Institute. GOG 0209. Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=305940&protocolsearchid=5821250&version= health professional
Downloads
Published
2009-12-30
How to Cite
1.
รายยวา ท. บทบาทของรังสีรักษาและเคมีบำบัดในมะเร็งมดลูก. J Thai Assn of Radiat Oncol [Internet]. 2009 Dec. 30 [cited 2024 May 5];15(2):45-59. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/203536
Issue
Section
Case Reports
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
